Table 1 Strains used in this study.
Strain | Characteristics | LPS/O-Ag | O-Ag capsule | CLC | Attenuated | Source/Reference |
|---|---|---|---|---|---|---|
F. tularensis LVS (Type B) | Attenuated Live Vaccine Strain | + | + | + | N | Dr. May Chu, CDC |
LVS_P10 | LVS subcultured 10 consecutive days in broth CDMB | + | + | +++ | N | |
LVSΔ1423-22 | LVS deficient in CLC due to deletion of  genes encoding for glycosyltransferases | + | + | − | Y | |
WbtIG191V | O-Ag mutant of LVS due to point mutation in wbtI | − | − | + | Y | |
WbtIG191V_P10 | WbtIG101V subcultured 10 consecutive days in CDMB | − | − | +++ | Y | |
WbtIG191VΔ1423-22 | O-Ag and CLC deficient double mutant. WbtIG191V with deletion of FTL_1423 and 1422 | − | − | − | Y | |
WbtIG191V+ | Complemented strain of respective mutant with O-Ag restored | + | + | + | NDb | |
LVSΔ1423-22+ | Complemented strain of respective mutant with CLC restored | + | + | + | ND | |
KY99-3387 | Wild Type B strain | + | + | + | N | BEI Resources |
KY99-3387_P10 | KY99-3387 subcultured 10 consecutive days in broth CDMB | + | + | +++ | N | This work |
F. novicida U112 | Parent F. novicida strain | + | ND | +/− | N | Dr. Karen Elkins, FDA |
F. novicida_P10 | Strain U112 subcultured 10 consecutive days in CDMB | + | ND | +++ | N | |
F. novicidaΔ1212-18 | CLC-deficient strain of U112 due to loss of FTN_1212-1218 in CLC glycosylation locus | + | ND | − | Y | |
F. tularensis SchuS4 (Type A) | Virulent Type A strain parent | + | + | + | N | Dr. Mark Wolcott, USAMRIID |
F. tularensis TI0902 (Type A) | Highly virulent Type A strain parent | + | + | + | N | |
F. tularensis TIGB03 | Chemical mutant of TI0902 lacking O-Ag | − | − | + | Y |
